Fourth Annual Kidney-NExT Symposium: Inventing the future of kidney therapeutics
This annual one-day symposium, chaired by institute member of the Broad and faculty at Brigham and Women’s Hospital and Harvard Medical School, Dr. Anna Greka, will bring together leading stakeholders to discuss how we can advance the quest for novel therapeutics for kidney diseases, an area of tremendous unmet need. The Kidney-NExT Symposium (formerly Glom-NExT) is a unique forum for shared dialogue between academia and industry leaders, the FDA and patients from across the country to shape the future of kidney treatments.
Thursday April 12, 2018
Broad Institute,
415 Main St. Cambridge, MA
Symposium Program
9:00 am
Welcome
Eric Lander and Anna Greka
Session 1
Towards precision medicines for kidney diseases
Chair: Kirk Campbell
9:15 am – 9:40 am
Kidney organoids: a human model system for precision medicine?
Joseph Bonventre
9:40 am – 10:05 am
Single cell genomics of the kidney
Benjamin Humphreys
10:05 am – 10:30 am
Single cell genomics in lupus nephritis: an immunologist’s view
Nir Hacohen
10:30 am – 10:55 am
A new approach to precision medicines for kidney diseases
Anna Greka
10:55 am – 11:10 am
Coffee Break
Session 2
Keynote Address
Chair: Steve Somlo
11:10 am – 12:00 pm
Lessons from decades in drug development
David Meeker
Former head of Sanofi-Genzyme, current CEO of KSQ Therapeutics
Clinical trial design and endpoints
Howard Trachtman
Session 4
Drug development redux: from rare to common (kidney) diseases
Chair: Ray Harris
1:50 pm – 2:15 pm
The patient perspective
Kevin Fowler
2:15 pm – 2:40 pm
The Broad/academia perspective
Martin Drysdale
2:40 pm – 3:05 pm
The biopharma perspective
Anthony Muslin
3:05 pm – 3:30 pm
The FDA perspective
Aliza Thompson
Roundtable discussion and brainstorming session: How can we do better?
Facilitator: Ray Harris
3:30 pm – 5:00 pm
Leaders from academia, biotech/pharma, FDA and patient advocates will spearhead the discussion in this brainstorming session, where we will explore how we can impact the discovery of novel therapeutics for kidney diseases